CDXS stock icon

Codexis
CDXS

$2.94
4.98%
 

About: Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.

Employees: 174

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

50% more call options, than puts

Call options by funds: $30K | Put options by funds: $20K

3% more funds holding

Funds holding: 118 [Q4 2023] → 122 (+4) [Q1 2024]

3% more capital invested

Capital invested by funds: $182M [Q4 2023] → $187M (+$4.93M) [Q1 2024]

9.26% less ownership

Funds ownership: 85.62% [Q4 2023] → 76.36% (-9.26%) [Q1 2024]

15% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 48

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
206%
upside
Avg. target
$9.67
229%
upside
High target
$11
274%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Kristen Kluska
274%upside
$11
Overweight
Initiated
30 May 2024
Benchmark
Robert Wasserman
206%upside
$9
Buy
Reiterated
3 May 2024
Benchmark
Robert Wasserman
206%upside
$9
Buy
Upgraded
29 Feb 2024

Financial journalist opinion